News

The companies will develop joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities. "After recent discussions with

The Conception Kit at-home system contains a comprehensive collection of materials including 24 ovulation predictors, three pregnancy tests, and the innovative Conception Cap. Patients who purchased the same

The existing partnership is in the field of chronic obstructive pulmonary disease (COPD). Under the extended deal, the parties will set up a second team of scientists from

In Switzerland, the classification of "transplant products" includes cell therapies such as Apligraf. With marketing approval of Apligraf, Switzerland has become the first country in Europe to grant

TruSkin has been developed to provide healthcare professionals a new option for treating large, chronic wounds in the Hospital Outpatient, Private Office, and/or Surgical Settings, where allograft options

Each therapy will feature a mixture of synthetic messenger RNAs (mRNAs). BioNTech will receive $60m in upfront and near-term milestone payments. The company could also receive more than

The formulation for the spray includes three important ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation. Nise D Spray will

Dyax develops plasma kallikrein (pKal) inhibitors for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening disease that causes swelling. The deal gives Shire access to

Cardioxyl is focused on the discovery and development of novel therapeutic agents to treat cardiovascular disease. The transaction, which is expected to close in the fourth quarter, gives